Drug against covid-19 included in SUS is only for severe cases of the disease
The drug baricitinibalready used in prescriptions for rheumatoid arthritis, was incorporated into the Unified Health System (SUS) to treat covid-19. The use of the drug to combat the virus was approved by the National Health Surveillance Agency (Anvisa) in September 2021 and, despite Brazil having eight drugs authorized for the treatment of coronavirus, baricitinib is the first to be included in the SUS.
In a meeting of the National Commission for the Incorporation of Technologies in the Unified Health System (Conitec) convened on Wednesday, 30th, it was decided to guide the inclusion of the drug in the SUS that influences the recovery of inflammatory conditions through the immune system.
WHO IS THE DRUG INCLUDED IN SUS INDICATED FOR?
Treatment with the drug baricitinib is used in severe cases of covid-19. The prescription is only intended for patients who require oxygen by mask, high flow oxygen, non-invasive ventilation, or a nasal catheter.. Studies on the action of the drug indicate that the risk of death in hospitalized patients can be significantly reduced.
In 28 days of treatment, a study identified a 38% reduction in mortality from covid-19, in which 4mg of baricitinib was compared with placebo.. This week, Anvisa approved the drug Paxlovid (nirmatrelvir + ritonavir), from Pfizer, for emergency use.
Source: Recreio
